Zielgerichtete Systemtherapie beim operablen Lungenkarzinom

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

Abstract

Non-small cell lung cancer (NSCLC) is characterized by high recurrence rates in the early stages. In a German cohort, recurrence-free survival after 5 years was 62stage IA1), 40.7stage IIA) and 28stage IIIA). In addition to the perioperative use of immune checkpoint inhibitors, targeted tumor therapy is also making inroads as an innovation from the palliative setting into the early stages. Of particular relevance is the use of the EGFR inhibitor osimertinib, which has been shown to improve overall survival in the adjuvant setting. In this practice-oriented review, we briefly describe the current status of adjuvant targeted therapy and the associated testing and provide an outlook on further developments.
Translated title of the contribution
Perioperative Targeted Therapy for Operable, Early Stage NSCLC

Details

Original languageGerman
Pages (from-to)S45-S51
JournalZentralblatt fur Chirurgie
Volume149
Issue number01
Publication statusPublished - 1 Aug 2024
Peer-reviewedYes

External IDs

Scopus 85201246786
ORCID /0000-0002-4095-8649/work/172086473

Keywords

Keywords

  • NSCLC, Osimertininb, ADAURA, FLAURA